XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

Core Points - XORTX Therapeutics Inc. has entered into a securities purchase agreement for the sale of 1,746,631 common shares at a price of US$0.63 per share, aiming to raise gross proceeds of US$1.1 million [1][2] Group 1: Offering Details - The closing of the offering is expected on or about October 22, 2025, pending customary closing conditions and TSX Venture Exchange approval [2] - The net proceeds from the offering will be used for working capital and general corporate purposes [2] - D. Boral Capital LLC is acting as the sole placement agent for the offering [3] Group 2: Regulatory Information - The common shares will be issued under an effective shelf registration statement previously filed with the SEC [4] - A prospectus supplement detailing the terms of the offering will be filed with the SEC and will be available on their website [4] Group 3: Company Overview - XORTX is focused on developing therapies for gout and progressive kidney disease, with three clinically advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [6] - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy [6] - XORTX aims to improve the quality of life for individuals with gout and related diseases by targeting purine metabolism and xanthine oxidase to reduce uric acid production [6]